Invivyd : Corporate Presentation – September 2023

CORPORATE OVERVIEW

September 2023

© 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "seek," "could," "intend," "target," "aim," "project," "designed to," "estimate," "believe," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward- looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning, among other things, our mission to rapidly deliver antibodies that protect vulnerable populations from viral threats; the future of the COVID-19 landscape; our expectations regarding the size of target patient populations and the potential market opportunity for our product candidates, as well as our market position; our beliefs regarding the clinical utility of anti-SARS-CoV-2 monoclonal antibodies (mAbs) and our product candidates; the potential of our platform-based approach to continuously discover and optimize mAb candidates that can perpetually protect the vulnerable from serious viral threats; the anticipated broad activity and prolonged utility of VYD222; our ongoing research and clinical development plans and the timing thereof, including with respect to VYD222; the possibility of a unique, rapid development pathway to potential emergency use authorization (EUA) in the U.S. for mAbs using immunobridging via serum neutralizing titers; the anticipated CANOPY clinical trial design, including our plans to use an immunobridging approach comparing data obtained in the CANOPY clinical trial to certain historical adintrevimab data; our expectation to rapidly generate clinical data in the CANOPY clinical trial for a potential VYD222 EUA submission, and the timing of anticipated initial primary endpoint data from the CANOPY clinical trial; our plans to generate a robust pipeline of product candidates which, if authorized or approved, could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications; our belief that our existing cash resources will be sufficient to support operating runway into the fourth quarter of 2024; and other statements that are not historical fact. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the timing and progress of our discovery, preclinical and clinical development activities; our ability to rapidly generate the clinical data needed from the CANOPY clinical trial to support a potential EUA submission for VYD222; clinical trial site activation or enrollment rates that are lower than expected; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of VYD222 or other product candidates based on neutralizing activity in preclinical studies; the risk that results of preclinical studies or clinical trials may not be predictive of future results in connection with current or future clinical trials; variability of results in models used to predict activity against SARS- CoV-2 variants of concern; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; whether our platform-based approach enables us to continuously discover and optimize mAb candidates that can perpetually protect the vulnerable from serious viral threats; whether VYD222 or any other product candidate is able to demonstrate and sustain neutralizing activity against predominant SARS-CoV-2 variants, particularly in the face of viral evolution; whether we are able to successfully submit an EUA in the future, and the outcome of any such EUA submission; whether our research and development efforts will identify and result in safe and effective therapeutic options for infectious diseases other than COVID-19; and whether we have adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this presentation are described under the heading "Risk Factors" in our most recent Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (SEC), and in our other filings with the SEC, and in our future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this presentation are made as of this date, and we undertake no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.

© 2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.

2

INVIVYD IS ON A MISSION TO RAPIDLY DELIVER ANTIBODIES THAT PROTECT VULNERABLE POPULATIONS FROM VIRAL THREATS, STARTING WITH COVID-19

8-18M	Zero	Near-Term Opportunity
immunocompromised people	authorized or approved	EUA pathway provides the
in the U.S. alone who may not	monoclonal antibodies	opportunity to rapidly bring a
adequately respond to	(mAbs) in the U.S. to	much needed therapeutic to
COVID-19vaccination1-4	prevent symptomatic	immunocompromised people
	COVID-19

References: 1. Harpaz JAMA 2016; 2. Patel Emerg Infect Dis 2020; 3. U.S. 2020 Census Bureau Data; 4. Lee BMJ 2022

3

MANY IMMUNOCOMPROMISED PEOPLE HAVE AN IMPAIRED RESPONSE TO VACCINES AND LESS PROTECTION AGAINST SEVERE COVID-19 OUTCOMES

Immunocompromised people are less likely to have detectable SARS- CoV-2 antibodies following vaccination than immunocompetent people

Seroconversion rates (detectable Abs) in immunocompromised people vs. immunocompetent controls after two COVID-19 vaccine doses1 [pre-Omicron]

Immunocompromised people generate less protection against severe outcomes than immunocompetent people after bivalent boosters

Vaccine effectiveness against COVID-19-associatedhospitalizations after bivalent booster compared with no vaccination2

Seroconversion rates (%)

100%

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%

		Immunocompetent		Immunocompromised
98%	98%	98%

74%

62%

43%

Haematological	Organ	Immune-Mediated
cancers	Transplant	Inflammatory
(Weighted average	(Weighted average	Disorders
of 19 studies)	of 24 studies)	(Weighted average
		of 17 studies)

Vaccine effectiveness (%)

100%

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%

		Immunocompetent		Immunocompromised

62%

28%	24%
	13%
7-59 days	120-179 days
post bivalent booster	post bivalent booster

References: 1. Lee BMJ 2022 ; 2. Centers for Disease Control and Prevention, Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023; Abs, antibodies

4

EVEN IN PRIMARILY IMMUNOCOMPETENT POPULATIONS, COVID-19 VACCINE EFFECTIVENESS (VE) HAS WANED

Monovalent boosters provided 90% VE against symptomatic Delta infection vs. 46% VE against symptomatic Omicron infection

VE against symptomatic COVID-19 in primarily immunocompetent1

Monovalent (BNT162b2)	≥10 wks from monovalent booster
(following two doses of monovalent vaccine)
Delta B.1.617.2	90%
Omicron B.1.1.529	46%

Bivalent boosters have shown 4-29% VE against infection with more recent Omicron variants

VE against SARS-CoV-2 infection in primarily immunocompetent2

Bivalent Booster	Up to 26 wks from
bivalent booster
Omicron BA.4/5 dominant phase	29%
Omicron BQ dominant phase	20%
Omicron XBB dominant phase	4%

A mAb therapeutic that offers more robust protection against current variants would be an important

addition to the COVID-19 medicine cabinet, especially for vulnerable populations

References: 1. Andrews N Engl J Med 2022; 2. Shrestha Open Forum Infectious Diseases 2023

5